Your browser doesn't support javascript.
loading
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
Patel, Jyoti D; Paz-Ares, Luis; Zinner, Ralph G; Barlesi, Fabrice; Koustenis, Andrew G; Obasaju, Coleman K.
Afiliação
  • Patel JD; Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL. Electronic address: jpatel25@medicine.bsd.uchicago.edu.
  • Paz-Ares L; University Hospital Doce de Octubre & Research Institute, Madrid, Spain.
  • Zinner RG; Department of Medical Oncology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA.
  • Barlesi F; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
  • Koustenis AG; Oncology at Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
  • Obasaju CK; Oncology at Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Clin Lung Cancer ; 19(6): e823-e830, 2018 11.
Article em En | MEDLINE | ID: mdl-30369427
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Pemetrexede / Bevacizumab / Imunoterapia / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Pemetrexede / Bevacizumab / Imunoterapia / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article